{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T02:56:03Z","timestamp":1787626563425,"version":"build-2736575974"},"reference-count":34,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010607","name":"University of Perugia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010607","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/00x27da85","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Gram-positive infections are associated with significant morbidity and healthcare burden, often requiring prolonged intravenous therapy. Dalbavancin, a long-acting lipoglycopeptide, has emerged as a promising option beyond its approved indication for acute bacterial skin and skin structure infections (ABSSSI). A systematic review was conducted according to the PRISMA guidelines (PROSPERO: CRD420261296328). MEDLINE, Embase, CENTRAL, and Web of Science were searched from inception. Randomized controlled trials (RCTs) and observational studies evaluating dalbavancin in adult patients with Gram-positive infections were included. Outcomes of interest were clinical effectiveness, safety, and healthcare resource utilization. Risk of Bias was assessed using RoB 2 and the Newcastle\u2013Ottawa Scale. Twenty-one studies were included. Randomized trials confirmed non-inferior efficacy of dalbavancin compared with standard therapy in ABSSSI. Observational studies demonstrated high clinical success rates across a range of infections, including osteo-articular infections, bloodstream infections, and infective endocarditis (IE), particularly in acute settings. Lower effectiveness was observed in biofilm-related infections without adequate source control. Dalbavancin was frequently used as sequential or consolidation therapy in complex patients. Its use was consistently associated with reduced length of hospital stay, facilitation of outpatient management, and potential cost savings. The safety profile was favorable, including in prolonged or multi-dose regimens. In conclusion, dalbavancin represents an effective and well-tolerated option for Gram-positive infections, with expanding evidence supporting its use in complex and off-label settings. Its pharmacokinetic profile enables simplified treatment strategies and improved healthcare resource utilization, although appropriate patient selection and source control remain essential.<\/jats:p>","DOI":"10.3390\/microorganisms14051071","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T10:50:52Z","timestamp":1778496652000},"page":"1071","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dalbavancin in the Real-World Management of Gram-Positive Infections: A Systematic Review of Randomized and Observational Studies"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9162-7866","authenticated-orcid":false,"given":"Claudio","family":"Tana","sequence":"first","affiliation":[{"name":"Internal Medicine Unit, Eastern Hospital, ASL Taranto, 74024 Manduria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Moffa","sequence":"additional","affiliation":[{"name":"Infectious Disease Clinic, G. D\u2019Annunzio University of Chieti and ASL2 Lanciano Vasto Chieti, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0899-9870","authenticated-orcid":false,"given":"Marco","family":"Tana","sequence":"additional","affiliation":[{"name":"Internal Medicine Unit, G. D\u2019Annunzio University of Chieti and ASL2 Lanciano Vasto Chieti, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samanta","family":"Moffa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, G. D\u2019Annunzio University of Chieti, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5866-3849","authenticated-orcid":false,"given":"Claudio","family":"Ucciferri","sequence":"additional","affiliation":[{"name":"Infectious Disease Clinic, University of Perugia, 06123 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"106763","DOI":"10.1016\/j.ijantimicag.2023.106763","article-title":"Off-label use versus formal recommendations of conventional and novel antibiotics for the treatment of infections caused by multidrug-resistant bacteria","volume":"61","author":"Jean","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Moffa, L., and Tana, C. (2025). Healthcare-Associated Infections (HAIs) in the Elderly: Molecular Mechanisms of Immunosenescence and Clinical, Nutritional and Therapeutic Implications. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26199649"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"107581","DOI":"10.1016\/j.ijantimicag.2025.107581","article-title":"Long-acting lipoglycopeptides compared to standard-of-care for the treatment of complicated gram-positive infections: A systematic review and meta-analysis","volume":"66","author":"Salvatore","year":"2025","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1017\/ash.2025.10281","article-title":"A bundle of the top 10 OPAT publications in 2024","volume":"6","author":"Azimi","year":"2026","journal-title":"Antimicrob. Steward. Healthc. Epidemiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"T396","DOI":"10.1016\/j.farma.2025.08.003","article-title":"Therapeutic drug monitoring of dalbavancin: A systematic review of strategies and clinical applications in the treatment of complex infections","volume":"49","year":"2025","journal-title":"Farm. Hosp."},{"key":"ref_6","first-page":"1222","article-title":"The current and future off-label uses of dalbavancin: A narrative review","volume":"27","author":"Fiore","year":"2023","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_7","first-page":"449","article-title":"The role of long-acting antibiotics in the clinical practice: A narrative review","volume":"31","author":"Micheli","year":"2023","journal-title":"Infez. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e0109225","DOI":"10.1128\/aac.01092-25","article-title":"Monthly dalbavancin dosing for suppressive therapy: A pharmacokinetic estimation analysis and case series","volume":"70","author":"Kufel","year":"2026","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Tana, C., Moffa, S., Tana, M., Ucciferri, C., and Moffa, L. (2025). Gut Microbiota, Mild Cognitive Impairment and Dementia: A Systematic Review. Neurol. Int., 17.","DOI":"10.3390\/neurolint17100155"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"L4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Br. Med. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"ofy331","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety","volume":"6","author":"Rappo","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1093\/jac\/dkac178","article-title":"Dalbavancin in Gram-positive periprosthetic joint infections","volume":"77","author":"Simon","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s15010-019-01354-x","article-title":"Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection","volume":"47","author":"Tobudic","year":"2019","journal-title":"Infection"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s15010-023-02152-2","article-title":"Experience with dalbavancin use in various gram-positive infections within Aberdeen Royal Infirmary OPAT service","volume":"52","author":"McSorley","year":"2024","journal-title":"Infection"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40121-019-00275-4","article-title":"Dalbavancin Reduces Hospital Stay and Improves Productivity for Patients with Acute Bacterial Skin and Skin Structure Infections: The ENHANCE Trial","volume":"9","author":"McCarthy","year":"2020","journal-title":"Infect. Dis. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"dlad044","DOI":"10.1093\/jacamr\/dlad044","article-title":"Cost analysis of dalbavancin versus standard of care for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in two Italian hospitals","volume":"5","author":"Bai","year":"2023","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1080\/14787210.2020.1798227","article-title":"Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: Data from an Italian observational multicentric study (DALBITA study)","volume":"18","author":"Bai","year":"2020","journal-title":"Expert. Rev. Anti-Infect. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Parruti, G., Polilli, E., Coladonato, S., Rapacchiale, G., Trave, F., Mazzotta, E., Bondanese, M., Di Masi, F., Recinelli, D., and Corridoni, S. (2024). Safety and Efficacy of Dalbavancin in Real Life: Retrospective Analysis of a Large Monocentric Case Series of Patients Treated for Skin\/Soft Tissue and Other Difficult-to-Treat Infections. Antibiotics, 13.","DOI":"10.3390\/antibiotics13111063"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40121-024-00933-2","article-title":"Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study","volume":"13","author":"Rebold","year":"2024","journal-title":"Infect. Dis. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"105035","DOI":"10.1016\/j.idnow.2025.105035","article-title":"Dalbavancin for prosthetic joint infections: Empirical treatment","volume":"55","author":"Mairesse","year":"2025","journal-title":"Infect. Dis. Now"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/ejhpharm-2020-002315","article-title":"Effectiveness, safety and cost analysis of dalbavancin in clinical practice","volume":"29","year":"2022","journal-title":"Eur. J. Hosp. Pharm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12941-019-0329-6","article-title":"DALBACEN cohort: Dalbavancin as consolidation therapy in patients with endocarditis and\/or bloodstream infection produced by gram-positive cocci","volume":"18","author":"Vinuesa","year":"2019","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.eimc.2024.04.009","article-title":"Dalbavancin as sequential therapy in infective endocarditis: Real-life experience in elder and comorbid patients","volume":"43","author":"Heredia","year":"2025","journal-title":"Enferm. Infecc. Microbiol. Clin. (Engl. Ed.)"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jmii.2025.03.001","article-title":"Real-world evidence of dalbavancin effectiveness as consolidation therapy in infective endocarditis due to Enterococcus spp.","volume":"58","author":"Plata","year":"2025","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"106918","DOI":"10.1016\/j.ijantimicag.2023.106918","article-title":"EN-DALBACEN 2.0 Cohort: Real-life study of dalbavancin as sequential\/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci","volume":"62","author":"Loeches","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_27","first-page":"296","article-title":"Experience in the use of dalbavancin in diabetic foot infection","volume":"40","year":"2022","journal-title":"Enferm. Infecc. Microbiol. Clin. (Engl. Ed.)"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"334","DOI":"10.37201\/req\/012.2024","article-title":"Dalbavancin as consolidation therapy for infective endocarditis in patients with comorbidity. A real world experience","volume":"37","year":"2024","journal-title":"Rev. Esp. Quimioter."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jgar.2023.11.015","article-title":"Dalbavancin real-life utilization among diabetic patients suffering from infections in Italy and Spain: The DALBADIA retrospective cohort study","volume":"36","author":"Ruggieri","year":"2024","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_30","first-page":"35","article-title":"Clinical use of dalbavancin in the Italian SUSANA cohort (SUrveillance of SAfety and outcome of New Antibiotics)","volume":"48","author":"Tordi","year":"2025","journal-title":"New Microbiol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Ciusa, G., Pipitone, G., Mancuso, A., Agrenzano, S., Imburgia, C., Geraci, A.M., D\u2019Alcamo, A., Moscarelli, L., Cascio, A., and Iaria, C. (2025). One-Shot, One Opportunity: Retrospective Observational Study on Long-Acting Antibiotics for SSTIs in the Emergency Room-A Real-Life Experience. Pathogens, 14.","DOI":"10.3390\/pathogens14080781"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Moffa, L., Tana, C., Ucciferri, C., Moffa, S., Vecchiet, J., and Falasca, K. (2025). URO-RESIST: A Real-World Retrospective Study on Multidrug-Resistant Sepsis with Urinary Tract Infection, Clinical Predictors, Inflammatory Biomarkers, and Patient Outcomes. Antibiotics, 14.","DOI":"10.2139\/ssrn.5413404"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Tana, C., Siniscalchi, C., Cerundolo, N., Meschi, T., Martelletti, P., Tana, M., Moffa, L., Wells-Gatnik, W., Cipollone, F., and Giamberardino, M.A. (2025). Smart aging: Integrating AI into elderly healthcare. BMC Geriatr., 25.","DOI":"10.1186\/s12877-025-06723-w"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Tana, C., Soloperto, M., Giuliano, G., Erroi, G., Di Maggio, A., Tortorella, C., and Moffa, L. (2025). Artificial Intelligence for Predicting Lung Immune Responses to Viral Infections: From Mechanistic Insights to Clinical Applications. Viruses, 17.","DOI":"10.3390\/v17111482"}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/14\/5\/1071\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T04:31:53Z","timestamp":1778560313000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/14\/5\/1071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["microorganisms14051071"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms14051071","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]}}}